Millions of people are affected by so-called “diseases of the poor” in low and middle income countries. However, there are inadequate drugs, vaccines, diagnostics, and other resources to address these health challenges. Recently, a number of innovative ideas have emerged on how to address this gap, through the creation of new funding streams, incentives for scientists and biopharma companies, and changes in intellectual property arrangements and in regulatory institutions and practices.
With so many new and promising ideas, funders, policy-makers and other interested parties urgently require politically neutral and analytically sound assessments of these proposals. To meet this need, R4D has recently launched a new three-year project, Assessing Innovations in Global Health R&D Policy and Financing. This project aims to expand and improve the information used by governments, philanthropists, and private investors in making decisions on innovative schemes for financing and policies to drive global health R&D.
With grant support from the Bill & Melinda Gates Foundation, R4D will create a new center to assess likely impact, cost, feasibility, and risks associated with various global health R&D policy proposals. Led by Managing Director Robert Hecht, the R4D team and its partners will conduct rigorous independent reviews of these proposals, augmented by extensive research and consultations with a wide range of stakeholders, and will widely disseminate their findings.
“Through this initiative, we hope to provide a rigorous and independent view of the leading global health R&D policy proposals, and thereby stimulate dialogue and action that will lead to the accelerated development of life-saving health products” said Hecht.
For more information, please refer to the Assessing Innovations in Global Health R&D Policy and Financing project page.